Cited by

• Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications.

  Arnon R, Aharoni R. Arnon R, et al. Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2(Suppl 2):14593-8. doi: 10.1073/pnas.0404887101. Epub 2004 Sep 15. Proc Natl Acad Sci U S A. 2004. PMID: 15371592 Free PMC article.
• Assessing the In Vitro Potential of Glatiramer Acetate (Copaxone^®) as a Chemotherapeutic Candidate for the Treatment of Cryptococcus neoformans Infection.

  Alves V, Martins PH, Miranda B, de Andrade IB, Pereira L, Maeda CT, de Sousa Araújo GR, Frases S. Alves V, et al. J Fungi (Basel). 2023 Jul 25;9(8):783. doi: 10.3390/jof9080783. J Fungi (Basel). 2023. PMID: 37623554 Free PMC article.
• New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.

  Arnon R, Sela M, Teitelbaum D. Arnon R, et al. J Neurol. 1996 Apr;243(4 Suppl 1):S8-13. doi: 10.1007/BF00873696. J Neurol. 1996. PMID: 8965119 Review.
• Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.

  Kleist C, Mohr E, Gaikwad S, Dittmar L, Kuerten S, Platten M, Mier W, Schmitt M, Opelz G, Terness P. Kleist C, et al. J Transl Med. 2016 May 1;14(1):99. doi: 10.1186/s12967-016-0860-6. J Transl Med. 2016. PMID: 27131971 Free PMC article.
• Risk-benefit assessment of glatiramer acetate in multiple sclerosis.

  Ziemssen T, Neuhaus O, Hohlfeld R. Ziemssen T, et al. Drug Saf. 2001;24(13):979-90. doi: 10.2165/00002018-200124130-00005. Drug Saf. 2001. PMID: 11735654